116 results about "Oral mucous membrane" patented technology

The invention discloses a biological type drug membrane and a preparation method thereof. The main components of the biological type drug membrane are leaven and additives including film-forming material, plasticizer, aromatic and so on. The making process flow of the drug membrane is as follows: firstly the slurry of the film-forming material is prepared; inactivated leaven and the additives are added and evenly mixed, and then the processes of deaeration, coating, drying, deciduation and packing are carried out. Compared with the prior art, by adopting the leaven as the main component, the drug membrane not only plays a role of protecting a wound surface but also improves the nutrient metabolism of oral mucosa, protects various cell injuries and enhances body immunity. In addition, the drug membrane has the characteristics of small volume and light weight and is also more convenient for being easy to be packed, stored, transported, carried over and used. The biotype-drug membrane is mainly used for treating various congestion, erosion and ulcerous lesion. And the biological type drug membrane has good effect on treating recurring Aphthous ulcer and oral lichen planus (congestive and erosive type).

A medicament used for prophylactic and/or therapeutic treatment of xerostomia, which is in the form for oral mucosal administration comprising a spirooxathiolane quinuclidine derivative represented by the following general formula (I) or an acid addition salt thereof:

[Formula 1]

(wherein R¹ and R² may be the same or different, and independently represent a hydrogen atom, an alkyl group, a cyclopentyl group, a cyclohexyl group, a monoaryl- or diaryl-substituted methylol group, or an aryl-substituted alkyl group) as an active ingredient.

The invention provides the application of a 1,6-fructose diphosphate sodium salt, fructose and / or borneol composition to the preparation of an antiepileptic drug. The composition consists of 1,6-fructose diphosphate sodium salt and fructose, or 1,6-fructose diphosphate sodium salt and borneol combination, or 1,6-fructose diphosphate sodium salt, fructose and borneol. The composition provided by the invention can improve in vivo stability of 1, 6 1,6-fructose diphosphate, in order to maintain high level of 1,6-fructose diphosphate in the brain for a long time and make the 1,6-fructose diphosphate sodium salt exert antiepileptic effect for a long time. The composition provided by the invention particularly employs chewable tablets, orally disintegrating tablets and dispersible tablets as dosage forms for the antiepileptic drug, and the dosage forms can be directly absorbed in oral mucosa, avoid hepatic first-pass effect and further increase the level of 1,6-fructose diphosphate in the brain, thereby further improving the antiepileptic efficacy of the drug.

The present invention belongs to the field of medicine technology, and is especially oral loratadine disintegrating tablet for treating allergic diseases and its preparation process. The oral loratadine disintegrating tablet includes loratadine as effective medicine component, and excipient mixture comprising disintegrating agent, stuffing, soluble polyol and penetrant. The oral loratadine disintegrating tablet consists of loratadine 20-50 wt%, disintegrating agent 5-15 wt%, stuffing 10-30 wt%, soluble polyol 30-60 wt%, and penetrant 1-5 wt%. The oral loratadine disintegrating tablet, after being disintegrated fast, can cover gastrointestinal mucous membrane widely, and has fast acting, no first pass effect, high bioavailability, and convenient taking.

The invention discloses an application of cobrotoxin in preparing a medicine for treating arthritis. Cobrotoxin is a neurotoxin purified from Chinese cobra-venom. People research discovers that the cobrotoxin in the range of 1-600mug/kg has obvious effect on treating rheumatoid arthritis, can relieve the symptoms of arthrocele, arthralgia and the like, and has the advantages of small dose, safety,capability of oral administration, injectability, administration through oral mucous membrane, nasal mucous membrane and skin, and the like.

The present invention provides a pharmaceutical tablet comprising an orally disintegrating tablet core and an excipient coating adhered thereto, wherein the coating comprises gellan gum. The tablet is suitable for oral administration, for example, the drug contained in the core of the tablet is at least partially absorbed through the oral mucosa of the patient and delivered to the patient.

The invention relates to application of an allograft acellular dermal matrix in oral diseases, in particular to application of the allograft acellular dermal matrix in the repairing of cleft lip and/or alveolar cleft, cleft palate and oral mucous membrane defect, the repairing of periodontal defect and gingival recession, the repairing of nasal mucosa, tooth implantation, the repairing of furcation involvement and the prevention of complications such as dry socket after impacted tooth extraction, and belongs to the technical field of biological medical material tissue engineering. The allograft acellular dermal matrix is a product improved by a process, the mechanical performance of the product is suitable for surgery, and the sewing strength of the product is 16-18N; the allograft acellular dermal matrix is free of immunological rejection, capable of fast inducing tissue regeneration, soft in texture after implantation, free of contour feeling and good in in-vivo compatibility and hasa stable stent and template effect.

The invention discloses application of cobra venom in preparation of a medicament for treating lung inflammatory disease and pulmonary fibrosis. Animal experiment proves that Chinese cobra venom can alleviate acute endotoxin poisoning symptom within a range of 10-3000mug/kg, particularly has obvious therapeutic action on lung inflammatory disease caused by endotoxin, and can be used for alleviating inflammatory cell infiltration, alveolar septum thickening, and focal atelectasis and emphysema. Repeated small dose of endotoxin can result in pulmonary fibrosis, the cobra venom can significantly alleviate pulmonary fibrosis symptom and reduce alveoli damage and collagen hyperplasia. Naturally-modified Chinese cobra venom and physically-modified Chinese cobra venom have similar actions, but the physically-modified Chinese cobra venom has better action. Used for treating lung inflammatory disease, the Chinese cobra venom has the advantages of low dose, safety, capability of being orally administrated, injected, and administered through oral mucous membrane and skin and the like.

The present invention relates to medicine and its production and aims at raising biological utilization of oral absorption and strengthening the stability of the preparation. The insulin spray for oral cavity contains insulin 10000-70000 U, soybean lecithin 5-50 g and propylene glycol 25-80 g as well as borneol 1.2-10g, absolute ethyl alcohol 1-15 ml and phenol 2-5 g, the rest is pH 6.8-7.8 buffering phosphate solution, in each 1000 ml of microemulsion. The preparation process includes mixing soybean lecithin with propylene glycol, borneol and ethanol solution, addition of phenol containing buffering phosphate solution, supersonic treatment to obtain emulsified oil phase, the dissolution of insulin in the buffering solution, further mixing and supersonic treatment.

The invention provides a method for producing pure mountain ginseng lozenge, and relates to an improvement of health product, and the producing method comprises the following steps: 1. drying and crushing mountain ginseng, sieving mountain ginseng powder with a 80-800 mesh sieve, and mixing mountain ginseng powder and distilled water according to feed liquid weight ratio 1:20, extracting for three times, each of which lasts for 18 min or more, filtering, merging filtrates, and drying residue; 2. condensing the filtrate below 60 DEG C till the relative density of the extract is 1.10-1.15; 3. mixing the dried residue and the extract, adding distilled water and diluting till the relative density is 1.3-1.4, preparing the mixed mountain ginseng extract and the residue into wet particles, and drying at 68-75 DEG C; 4. compacting the wet particles into tablets by rotary type tablet press. The invention has the advantages that the oral mucosa and the oral gastrointestinal tract absorption pathway are combined, thereby the active ingredients in the mountain ginseng powder can be rapidly absorbed by human body, and the original flavour of the mountain ginseng is maintained, and the health care function is improved, moreover, the dosage is greatly reduced, and the utilization rate of the rare resource is increased.

A support steel alloy material for dentistry belongs to the technical field of dentistry materials. Chemical elements and weight percentages of the support steel alloy material include that cobalt takes 62%-64%, chromium takes 28%-30%, molybdenum takes 4%-5%, titanium takes 0.3%-1.2%, silicon takes 0.2%-1.3%, iron takes 0.2%-1.0%, manganese takes 0.2%-1.3% and carbon takes 0.1%-1.2%. The support steel alloy material for dentistry provided by the technical scheme of the invention is fine in biocompatibility with human bodies, has fine corrosion resistance, has hemolysis rate lower than 5%, does not have acute systemic toxicity, has cytotoxicity which is not higher than I level, and does not have oral mucous membrane irritation or delayed contact sensitization, and then the support steel alloy material has perfect safety. In addition, because the support steel alloy material is 767.1-789 in tensile strength ob(MPa), 5.36-5.44 in elongation (%) and 392.8-411 in Vickers hardness, the support steel alloy material has appropriate strength, hardness and wear resistance and fine processing property, and can be adaptable to soft and hard tissue inside orals.

The invention discloses antibacterial paste for killing or inhibiting helicobacter pylori in the oral cavity and a preparation method thereof. The antibacterial paste comprises the following raw materials in parts by mass: 1 to 1.5 parts of lysozyme, 0.5 to 2.5 parts of lactoferrin, 0.5 to 2 parts of frankincense extract, 0.5 to 2 parts of herba ecliptae extract, 0.5 to 2 parts of minor radix buplenri extract, 0.5 to 2 parts of radix sophorae flavescentis extract, 0.5 to 2 parts of radix isatidis extract, 0.5 to 2 parts of fructus forsythiae extract, 0.5 to 2 parts of radix glycyrrhizae extract, 0.5 to 2 parts of radix stemonae extract, 0.5 to 2 parts of herba hedyotis extract, 0.5 to 2 parts of aloe extract, 0.5 to 2 parts of flos chrysanthemi extract, 0.5 to 2 parts of stevia rebaudianaextract, 0.5 to 2 parts of bletilla striata extract, 0.772.30 parts of aminocaproic acid and the balance of a toothpaste matrix. According to the antibacterial paste capable of killing or inhibiting the helicobacter pylori in the oral cavity provided by the invention, the oral antibacterial paste has the strong-effect lysozyme and frankincense oil, and plays a role in strongly killing the helicobacter pylori for dissolving and degrading helicobacter pylori cell membranes and reducing the adhesiveness of the helicobacter pylori cell membranes and oral mucosa.

The invention discloses a method for detecting and evaluating conjunctival irritation and mucous membrane irritation by using chicken embryo vascular system, comprising the following steps: (1) preparation of chorioallantoic membrane; (2) conjunctival irritation test; (3) sticking mold Stimulation test; (4) prediction model and classification, the present invention uses the standardized chicken embryo as the test system, and its vascular system at different stages of development is similar to the human eye conjunctiva and oral submucosa tissue, and the chicken embryo has a high degree of standardization, stable source and batch The difference between blood vessels is small, the vascular system has biological activity and function, the test system is simple and cheap, no special equipment is required, and the detection method is fast, sensitive and universal. The invention can detect and evaluate the conjunctival irritation and mucous membrane irritation of the substance to be tested from both qualitative and quantitative aspects. The method of the present invention can also replace living animals and human volunteers, and be directly used for the detection of conjunctival irritation and mucosal irritation of substances such as chemicals or cosmetics, and rapid screening, classification and identification thereof.

The invention relates to oral transmucosal pharmaceutical compositions comprising metformin or a pharmaceutically acceptable salt thereof, methods of using the compositions to treat various conditions, including diabetes, methods of preparing the compositions, and preparations for use in making the compositions.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.